NCT03671733 is a Phase 3 clinical trial of Liraglutide in Obesity, sponsored by Xiangya Hospital of Central South University.

Who is sponsoring NCT03671733?

NCT03671733 is sponsored by Xiangya Hospital of Central South University.

What drugs are being tested in NCT03671733?

Interventions in NCT03671733: Liraglutide, Exenatide, Exenatide Microspheres for Injection.

Is NCT03671733 still recruiting?

NCT03671733 is currently status unknown. Last updated 9 April 2021.

Last reviewed 2021-04-09 · How we verify

NCT03671733

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

Status unknown Phase 3 Last updated 9 April 2021

What this trial tests

Phase 3 trial testing Liraglutide in Obesity in 150 participants. Status unknown.

Timeline

1 September 2018

Primary endpoint
1 September 2022

1 September 2022

Quick facts

Lead sponsor	Xiangya Hospital of Central South University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	1 September 2018
Primary completion	1 September 2022
Estimated completion	1 September 2022
Sites	1 location across China

Drugs / interventions tested

Liraglutide (liraglutide) — full drug profile →
Exenatide (EXENATIDE) — full drug profile →
Exenatide Microspheres for Injection — full drug profile →

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Xiangya Hospital of Central South University

Who can join

Adults 18 to 65, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This studay evaluates the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist,including Liraglutide,Exenatide and Exenatide Microspheres for Injection,in the treatment of subjects who are overweight or obese.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.
Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, et al · · 2023 · cited 260× · PMID 36992862 · DOI 10.1016/j.eclinm.2023.101882
Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists.
Cimino G, Vaduganathan M, Lombardi CM, Pagnesi M, et al · · 2024 · cited 33× · PMID 38093506 · DOI 10.1002/ehf2.14560

Verify or expand the search:

Other trials of Liraglutide

Trials testing the same drug.

NCT07225816 — Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in · Phase 1 · recruiting
NCT06818292 — Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists · NA · completed
NCT06283641 — Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. · completed
NCT06501326 — Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease · Phase 4 · unknown
NCT05756764 — Anti-obesity Pharmacotherapy and Inflammation · active not recruiting

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03671733 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
Last refreshed: 9 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03671733.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing